Shanghai SIMOS 2024, whose seventh edition took place this week, is one of the most influential conferences in the field of ...

In addition to the SP-26 agreement, Kymanox is Silo’s regulatory partner for SPC-15, a targeted prophylactic treatment for stress-induced affective disorders including PTSD.

The Company reported a gross profit before changes in fair value of $2.9 million for the three months ended September 30, 2024, compared to $2.4 million for the same period in 2023. This growth was ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR ...

ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) will host a conference call at 12:30pm Eastern time, Thursday, ...

Albus Health Device Detects Early Warning Signs of Child Asthma Attacks Up To Five Days Before Onset Research presented at British Thoracic Society Winter Meeting demonstrates potential for ...

Shareholders who hold their shares in brokerage accounts or in "street name" will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker's particular ...

SmartMammo™’s AI algorithm now FDA cleared with GE HealthCare’s Senographe Pristina™, expanding access to enhanced cancer detection. The clearance enables RadNet’s DeepHealth and GE HealthCare ...

After the capital increase, the total nominal value of Bavarian Nordic A/S' share capital is DKK 788,548,570, which is made up of 78,854,857 shares of a nominal value of DKK 10 each, corresponding to ...

ZUG, Switzerland, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.

Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response ...

Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc.